SMMT Stock Analysis: Buy, Sell, or Hold?
SMMT - Summit Therapeutics Inc. Common Stock
$14.17
-0.61 (-4.10%)
▼
5d:
-9.83%
30d:
-17.41%
90d:
-9.89%
HOLD
MODERATE Confidence
Analysis Updated: Jun 5, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 9.0/10
Get Alerted When SMMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SMMT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SMMT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SMMT is currently trading at $14.16, which is considered oversold relative to its 30-day fair value range of $15.48 to $18.56.
Technical Outlook: Technically, SMMT is in a strong uptrend. The price is currently testing key support at $14.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: SMMT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $28.36 (+92.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SMMT is in a strong uptrend. The price is currently testing key support at $14.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: SMMT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $28.36 (+92.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$15.48 -
$18.56
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 92.0% below Wall St target ($28.36)
- CAUTION: 5-day price weakness (-9.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$15.48 -
$18.56
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$14.17
Resistance Level
$18.51
Current Trend
Strong Uptrend
Technical data as of
Jun 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.76
Wall Street Target
$28.36
(+92.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 08, 2026 12:52 PM ET
Data refreshes hourly during market hours. Next update: 1:52 PM
Data refreshes hourly during market hours. Next update: 1:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SMMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 52 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$106 | 59 HOLD |
